Tissue Factor Pathway Inhibitor Levels During Veno-Arterial Extracorporeal Membrane Oxygenation in Adults.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
20
2
2021
medline:
16
10
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Tissue factor pathway inhibitor (TFPI) has multiple anticoagulant properties. To our knowledge, no studies have measured TFPI levels in adult veno-arterial (VA) extracorporeal membrane oxygenation patients. We hypothesized that adult VA ECMO patients would have increased TFPI levels and slowed tissue factor triggered thrombin generation. Twenty VA ECMO patients had TFPI levels and thrombin generation lag time measured on ECMO day 1 or 2, day 3, and day 5. TFPI levels and thrombin generation lag time were compared against healthy control plasma samples. Mean TFPI levels were significantly higher in ECMO patients on ECMO day 1 or 2 = 81,877 ± 19,481 pg/mL, day 3 = 73,907 ± 26,690 pg/mL, and day 5 = 77,812 ± 23,484 pg/mL compared with control plasma = 38,958 ± 9,225 pg/mL (P < 0.001 for all comparisons). Median thrombin generation lag time was significantly longer in ECMO patients on ECMO day 1 or 2 = 10.0 minutes [7.5, 13.8], day 3 = 9.0 minutes [6.8, 12.1], and day 5 = 10.7 minutes [8.3, 15.2] compared with control plasma = 3.6 minutes [2.9, 4.2] (P < 0.001 for all comparisons). TFPI is increased in VA ECMO patients and tissue factor triggered thrombin generation is slowed. Increased TFPI levels could contribute to the multifactorial coagulopathy that occurs during ECMO.
Identifiants
pubmed: 33606392
doi: 10.1097/MAT.0000000000001322
pii: 00002480-202108000-00009
doi:
Substances chimiques
Anticoagulants
0
Lipoproteins
0
lipoprotein-associated coagulation inhibitor
0
Thrombin
EC 3.4.21.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
878-883Informations de copyright
Copyright © ASAIO 2021.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
Mazzeffi M, Greenwood J, Tanaka K, et al.: Bleeding, transfusion, and mortality on extracorporeal life support: ECLS Working Group on thrombosis and hemostasis. Ann Thorac Surg. 101: 682–689, 2016.
Cheng R, Hachamovitch R, Kittleson M, et al.: Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: A meta-analysis of 1,866 adult patients. Ann Thorac Surg. 97: 610–616, 2014.
Lo Coco V, Lorusso R, Raffa GM, et al.: Clinical complications during veno-arterial extracorporeal membrane oxigenation in post-cardiotomy and non post-cardiotomy shock: Still the achille’s heel. J Thorac Dis. 10: 6993–7004, 2018.
Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B: Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: Rapid onset and fast recovery. J Heart Lung Transplant. 37: 985–991, 2018.
Mazzeffi M, Hasan S, Abuelkasem E, et al.: Von Willebrand factor-GP1balpha interactions in venoarterial extracorporeal membrane oxygenation patients. J Cardiothorac Vasc Anesth. 33: 2125–2132, 2019.
Nair P, Hoechter DJ, Buscher H, et al.: Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth. 29: 288–296, 2015.
Mazzeffi M, Strauss E, Meyer M, et al.: Coagulation factor levels and underlying thrombin generation patterns in adult extracorporeal membrane oxygenation patients. Anesth Analg. 129: 659–666, 2019.
Granja T, Hohenstein K, Schüssel P, et al.: Multi-modal characterization of the coagulopathy associated with extracorporeal membrane oxygenation. Crit Care Med. 48: e400–e408, 2020.
Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 87: 8869–8873, 1990.
Maroney SA, Haberichter SL, Friese P, et al.: Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 109: 1931–1937, 2007.
Maroney SA, Mast AE: Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 38: 9–14, 2008.
Maroney SA, Hansen KG, Mast AE: Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr Opin Hematol. 20: 403–409, 2013.
Yamamuro M, Wada H, Kumeda K, et al.: Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 9: 491–497, 1998.
Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50: 803–813, 1988.
Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH: Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost. 83: 937–943, 2000.
Wood JP, Ellery PE, Maroney SA, Mast AE: Biology of tissue factor pathway inhibitor. Blood. 123: 2934–2943, 2014.
Mast AE: Tissue factor pathway inhibitor: Multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 36: 9–14, 2016.
Fischer T, Kuppe H, Koster A: Impact of heparin management on release of tissue factor pathway inhibitor during cardiopulmonary bypass. Anesthesiology. 100: 1040, 2004.
Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE: Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A. 110: 17838–17843, 2013.
Agledahl I, Brodin E, Svartberg J, Hansen JB: Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost. 102: 945–950, 2009.
Dielis AW, Castoldi E, Spronk HM, et al.: Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 6: 125–131, 2008.
Kojima T, Gando S, Kemmotsu O, et al.: Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: Role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth. 15: 60–64, 2001.
Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF: Quantification of heparin-induced TFPI release: A maximum release at low heparin dose. Br J Clin Pharmacol. 54: 627–634, 2002.
Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 19: 2251–2262, 1999.
Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF: Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 15: 2055–2062, 1995.
Tauber H, Ott H, Streif W, et al.: Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers. Anesth Analg. 120: 730–736, 2015.
Ameri A, Kuppuswamy MN, Basu S, Bajaj SP: Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 79: 3219–3226, 1992.
Al Otair HA, Abdel Gader AG, Khurshid SM, et al.: The levels of tissue factor pathway inhibitor in sepsis patients receiving prophylactic enoxaparin. Turk J Haematol. 33: 112–118, 2016.
Donahue BS, Gailani D, Mast AE: Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost. 4: 1011–1016, 2006.